Literature DB >> 12499473

Immunization and MS: a summary of published evidence and recommendations.

Olivier T Rutschmann1, Douglas C McCrory, David B Matchar.   

Abstract

OBJECTIVE: To review the risk of MS exacerbations after infectious episodes potentially preventable by vaccination, and the risks and benefits of immunizing patients with MS.
METHODS: The authors searched MEDLINE (1966 to January 2001; U.S. National Library of Medicine, Bethesda, MD), HealthSTAR, and Cumulative Index to Nursing and Allied Health Literature (CINAHL) database (Cinahl Information Systems, Glendale, CA) for English-language articles. Each study was summarized and rated for quality of evidence. Then feasible data were pooled and analyzed in meta-analysis.
RESULTS: The risk of contracting common infectious diseases in patients with MS is not well established. There is strong evidence for an increased risk of MS exacerbations during weeks around an infectious episode. There is strong evidence against an increased risk of MS exacerbation after influenza immunization. There is no evidence that hepatitis B, varicella, tetanus, or Bacille Calmette-Guerin vaccines increase the risk of MS exacerbations. Insufficient evidence was found for other vaccines.
CONCLUSIONS: Evidence supports 1) strategies to minimize the risk of acquiring infectious diseases that may trigger exacerbations of MS; and 2) the safety of using influenza, hepatitis B, varicella, tetanus, and Bacille Calmette-Guerin (BCG) vaccines in patients with MS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12499473     DOI: 10.1212/wnl.59.12.1837

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  24 in total

1.  Post-infectious and post-vaccinal acute disseminated encephalomyelitis occurring in the same patients.

Authors:  Sabrina Ravaglia; Mauro Ceroni; Arrigo Moglia; Alessandra Todeschini; Enrico Marchioni
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

2.  Frequent vaccination and immune complex deposition in unilateral nephrectomized mice.

Authors:  Semra Kurul; Salih Kavukcu; Banu Sis; Osman Yilmaz; Sulen Sarioglu; Alper Soylu; Mehmet Turkmen; Eray Dirik
Journal:  Pediatr Nephrol       Date:  2004-03-20       Impact factor: 3.714

Review 3.  Vaccination against infection in patients with multiple sclerosis.

Authors:  Micha Loebermann; Alexander Winkelmann; Hans-Peter Hartung; Hartmut Hengel; Emil C Reisinger; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2012-01-24       Impact factor: 42.937

Review 4.  [Multiple sclerosis and hepatitis B vaccination : What does the verdict of the European Court of Justice on liability after vaccination mean?]

Authors:  M Löbermann; B Handorn; A Winkelmann; E C Reisinger; H P Hartung; U K Zettl
Journal:  Nervenarzt       Date:  2018-10       Impact factor: 1.214

Review 5.  [Vaccination and multiple sclerosis].

Authors:  M Löbermann; A Winkelmann; E C Reisinger; U K Zettl
Journal:  Nervenarzt       Date:  2010-02       Impact factor: 1.214

6.  Relapse risk in patients with multiple sclerosis after H1N1 vaccination, with or without seasonal influenza vaccination.

Authors:  Nuala McNicholas; Jeremy Chataway
Journal:  J Neurol       Date:  2011-02-19       Impact factor: 4.849

7.  Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination.

Authors:  S Elizabeth Williams; Barbara A Pahud; Claudia Vellozzi; Peter D Donofrio; Cornelia L Dekker; Neal Halsey; Nicola P Klein; Roger P Baxter; Colin D Marchant; Philip S Larussa; Elizabeth D Barnett; Jerome I Tokars; Brian E McGeeney; Robert C Sparks; Laurie L Aukes; Kathleen Jakob; Silvia Coronel; James J Sejvar; Barbara A Slade; Kathryn M Edwards
Journal:  Vaccine       Date:  2011-09-03       Impact factor: 3.641

8.  Plasmacytoid dendritic cells in multiple sclerosis: chemokine and chemokine receptor modulation by interferon-beta.

Authors:  Latt Latt Aung; Patricia Fitzgerald-Bocarsly; Suhayl Dhib-Jalbut; Konstantin Balashov
Journal:  J Neuroimmunol       Date:  2010-09-14       Impact factor: 3.478

Review 9.  Vaccines in Multiple Sclerosis.

Authors:  Eric M L Williamson; Salim Chahin; Joseph R Berger
Journal:  Curr Neurol Neurosci Rep       Date:  2016-04       Impact factor: 5.081

Review 10.  Potential triggers of MS.

Authors:  Jane E Libbey; Robert S Fujinami
Journal:  Results Probl Cell Differ       Date:  2010
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.